Sugi Predict

Sugi Predict / Compounds / SCHEMBL3482749

SCHEMBL3482749

SCHEMBL3482749

[CH2]CN(CC)S(=O)(=O)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.57
▸ HTT P42858 3/20 0.57
▸ SMN1; SMN2 Q16637 5/20 0.55
▸ TSHR P16473 3/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ CNR2 P34972 1/20 0.51
▸ NPC1 O15118 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.49
▸ KMT2A Q03164 3/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ ESR1 P03372 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ PSIP1 O75475 1/20 0.47
▸ NR1I2 O75469 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ APOBEC3G Q9HC16 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2058156 0.88 LMNA (0.70) LMNAHTTSMN1; SMN2TSHRALDH1A1
SCHEMBL9657376 0.88 APOBEC3G (0.52) LMNAHTTSMN1; SMN2TSHRALDH1A1
SCHEMBL3483000 0.85 TDP1 (0.54) LMNAHTTSMN1; SMN2ALDH1A1CNR2
SCHEMBL13286823 0.84 LMNA (0.61) LMNAHTTSMN1; SMN2TSHRALDH1A1
SCHEMBL17567120 0.82 LMNA (0.59) LMNAHTTSMN1; SMN2TSHRALDH1A1
SCHEMBL3482729 0.82 TDP1 (0.65) LMNAHTTSMN1; SMN2CNR2RAB9A
SCHEMBL11598927 0.81 TDP1 (0.58) LMNAHTTSMN1; SMN2TSHRALDH1A1
SCHEMBL3483317 0.80 TAS2R14 (0.59) LMNAHTT
SCHEMBL11675019 0.80 LMNA (0.53) LMNAHTTSMN1; SMN2TSHRALDH1A1
Hydrochloric Acid SCHEMBL4598986 0.79 LMNA (0.56) LMNAHTTSMN1; SMN2TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103211811-B Stable pharmaceutical composition ASAHI KASEI PHARMA CORP 2015-06-10 — — CN disclosed
US-9006225-B2 Stable pharmaceutical composition ASAHI KASEI PHARMA CORPORATION (JP) 2015-04-14 — — US disclosed
CN-103211811-A Stable pharmaceutical composition ASAHI KASEI PHARMA CORP 2013-07-24 — — CN disclosed
EP-2236135-A1 STABLE PHARMACEUTICAL COMPOSITION Asahi Kasei Pharma Corporation (JP) 2010-10-06 — — EP disclosed
US-20100048893-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-02-25 — — US disclosed
US-20100041725-A1 STABLE PHARMACEUTICAL COMPOSITION ASAHI KASEI PHARMA CORPORATION (JP) 2010-02-18 — — US disclosed
EP-2006271-A9 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2009-07-29 — — EP disclosed
CN-101410366-A Substituted bicyclic ring derivatives and uses thereof ASAHI KASEI PHARMA CORP (JP) 2009-04-15 — — CN disclosed
US-20090062530-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-03-05 — — US disclosed
US-20090054401-A1 Substituted bicyclic derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-26 — — US disclosed
US-7470807-B2 Suppress production of both prostaglandins and leukotrienes and have reduced side effects; treatment of various inflammatory diseases, autoimmune diseases, allergic diseases, pain and fibrosis; for example, methyl 3-[3-acetylamino-4-cyclopentyloxy-5-(naphthalen-2-yl)phenyl]propionate ASAHI KASEI PHARMA CORPORATION (JP) 2008-12-30 — — US disclosed
EP-2006271-A2 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2008-12-24 — — EP disclosed
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHAMA CORPORATION (JP) 2007-09-13 — — US disclosed
CN-101031539-A Substituted arylalkanoic acid derivatives and use thereof ASAHI KASEI PHAMA CORP (JP) 2007-09-05 — — CN disclosed
EP-1660427-A4 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORP (JP) 2006-12-20 — — EP disclosed
EP-1660427-A1 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2006-05-31 — — EP disclosed
WO-2005016862-A1 SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF ASAHI KASEI PHARMA CORPORATION (JP) 2005-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054401-A1 Substituted bicyclic derivatives and use thereof LTB4R2, LTC4S, LTB4R LMNA 1739/4885HTT 4558/4885SMN1; SMN2 4143/4885
US-20100048893-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 LMNA 1846/4885HTT 4284/4885SMN1; SMN2 4831/4885
US-20070213333-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 LMNA 1846/4885HTT 4284/4885SMN1; SMN2 4831/4885
US-20100041725-A1 STABLE PHARMACEUTICAL COMPOSITION SLC5A1, SLC5A2, SLC2A9 LMNA 4054/4885HTT 438/4885SMN1; SMN2 1037/4885
US-20090062530-A1 Substituted arylalkanoic acid derivatives and use thereof CYSLTR1, CYSLTR2, LTB4R2 LMNA 1846/4885HTT 4284/4885SMN1; SMN2 4831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.